Collegium and Grünenthal settle Nucynta patent litigation
Collegium Pharmaceutical agreed to pay Grünenthal GmbH $17 million to end a patent suit and terminate their license tied to the Nucynta products.
SEC filing
Latest
1 story
Sign inSign in1 story
Collegium Pharmaceutical agreed to pay Grünenthal GmbH $17 million to end a patent suit and terminate their license tied to the Nucynta products.
SEC filing